Helicobacter pylori inactivated vaccine and application thereof

Through the combination of Helicobacter pylori inactivated extract and aluminum hydroxide adjuvant, the immune pathway combined with injection and oral administration is adopted to solve the side effects and drug resistance of existing treatment plans, and achieve efficient prevention of Helicobacter pylori infection , reducing the risk of adverse reactions.

CN118949025APending Publication Date: 2024-11-15BEIJING YUANMAO BIOTECHNOLOGY PARTNERSHIP (LLP) +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411185941.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing Helicobacter pylori treatment plan has problems such as many side effects of drugs, increased antibiotic-resistant strains and expensive treatment costs. The complex antigen components of the whole bacterial inactivated vaccine may cause adverse reactions, which limits its clinical application.

Method used

The vaccine is prepared by inactivated Helicobacter pylori extract as an immunogen, combined with aluminum hydroxide adjuvant, formaldehyde inactivation and high-pressure homogeneous crushing, providing the form of an injection or oral agent, and an immune pathway combining injection and oral administration is adopted.

Benefits of technology

It significantly improves immune efficiency, reduces the incidence of adverse reactions, induces strong humoral and cellular immune responses, and provides an effective prevention method for Helicobacter pylori infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949025A_ABST
    Figure CN118949025A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of helicobacter pylori vaccines, in particular to a helicobacter pylori inactivated vaccine and application thereof. The vaccine comprises an immunogen and an immunologic adjuvant, wherein the immunogen is a helicobacter pylori inactivated extract; the helicobacter pylori inactivated extract is obtained by carrying out formaldehyde inactivation on helicobacter pylori thalli and then carrying out high-pressure homogenization and crushing on the inactivated helicobacter pylori thalli. The inactivated whole bacteria of the helicobacter pylori are crushed and extracted, macromolecular antigens are released, the immune efficiency is remarkably improved under the cooperation of the adjuvant, and meanwhile, the occurrence rate of adverse reactions can be effectively reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of Helicobacter pylori vaccines, and in particular to an inactivated Helicobacter pylori vaccine and application thereof. Background Art

[0002] Helicobacter pylori ( Heloicobacter pylori Hp is the main pathogen that causes gastric ulcers, duodenal ulcers, gastric cancer and other digestive diseases, and has been listed as a Class I carcinogen by the World Health Organization (WHO). In addition, Hp is also closely related to some extraintestinal diseases such as diabetes, coronary heart disease, and thrombocytopenic purpura. Currently, antibiotics and proton pump inhibitors are mainly used in clinical treatment of Hp, but this treatment regimen still has the following problems: drug therapy has many side effects, such as bad breath, abdominal pain, nausea, vomiting, etc.; antibiotic-resistant strains are increasing; and the cost of treatment is relatively expensive for infected people in developing countries.

[0003] Immunization is expected to become the most effective and economical method to prevent HP infection. HP vaccine may become the ultimate solution to eradicate HP. Studies have found that immunizing mice with whole-bacterial inactivated vaccines can induce efficient local mucosal responses and reduce the number of HP colonization in the stomach. Suganya et al. used standard strains of HP-SS1 and ATCC26695 whole bacteria as antigens and aluminum phosphate as adjuvant to immunize mice, and found that the IgG titer value increased over time. Holmgren et al. used the newly developed adjuvant multi-mutated cholera toxin and formalin-inactivated HP whole bacteria as antigens to immunize mice, and found that the number of HP colonization in the mouse stomach decreased, serum IgG and mucosal IgA increased, and IFN-γ and IL-17 increased significantly. Although whole-bacterial inactivated vaccines can induce mucosal immunity and humoral immunity, their complex antigenic components may cause adverse reactions, thus limiting their clinical application.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides an inactivated Helicobacter pylori vaccine and application thereof.

[0006] Specifically, the technical solution of the present invention is as follows: In a first aspect, the present invention provides an inactivated Helicobacter pylori vaccine, which includes an immunogen and an immune adjuvant, wherein the immunogen is an inactivated Helicobacter pylori extract; the inactivated Helicobacter pylori extract is obtained by inactivating Helicobacter pylori cells with formaldehyde and then homogenizing and crushing them under high pressure.

[0007] Preferably, the present invention uses a PBS solution containing 0.4±0.1% formaldehyde for inactivation, and the inactivation conditions include: 25±5° C., 16±4 h.

[0008] Preferably, before and after the inactivation in the present invention, the Helicobacter pylori is washed with a PBS solution for 5±2 times respectively; the conditions for each washing include: 8000±1000 rpm, 5±1 min.

[0009] Preferably, the high pressure homogenization condition of the present invention is 600±100 bar.

[0010] Preferably, the immune adjuvant of the present invention is aluminum hydroxide adjuvant.

[0011] Preferably, the dosage form of the inactivated Helicobacter pylori vaccine of the present invention is an injection or an oral preparation.

[0012] In a second aspect, the present invention provides use of the inactivated Helicobacter pylori vaccine in the manufacture of a drug for creating an immune response in a subject, wherein the drug is in the form of an injection or an oral preparation.

[0013] In a third aspect, the present invention provides a pharmaceutical composition for creating an immune response in a subject, which comprises an injection of the inactivated vaccine; and also comprises an oral dosage of the inactivated vaccine.

[0014] In a fourth aspect, the present invention provides a method for preventing Helicobacter pylori infection, comprising the following steps: immunizing with the inactivated Helicobacter pylori vaccine or the pharmaceutical composition for creating an immune response in a subject.

[0015] Preferably, the immunization includes one injection immunization and two oral immunizations in sequence; the interval between the injection immunization and the first oral immunization is 1 week, and the interval between the two oral immunizations is 2 weeks.

[0016] Beneficial effects: The present invention provides an inactivated Helicobacter pylori vaccine and its application, wherein the vaccine comprises an immunogen and an immune adjuvant, wherein the immunogen is an inactivated Helicobacter pylori extract; the inactivated Helicobacter pylori extract is obtained by inactivating Helicobacter pylori cells with formaldehyde and then homogenizing and crushing them under high pressure. The present invention crushes and extracts the inactivated whole Helicobacter pylori cells to release macromolecular antigens, and has significantly improved immune efficiency with the cooperation of an adjuvant, and can also effectively reduce the incidence of adverse reactions. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be described below.

[0018] Figure 1 These are the test results of IL-4 expression levels of mouse T lymphocytes in each group after antigen stimulation in the examples of the present invention.

[0019] Figure 2 These are the results of detecting the IFN-γ expression levels of T lymphocytes of mice in each group after antigen stimulation in the examples of the present invention. DETAILED DESCRIPTION

[0020] The invention provides an inactivated Helicobacter pylori vaccine and application thereof.

[0021] First, the present invention provides an inactivated Helicobacter pylori vaccine, which includes an immunogen and an immune adjuvant, wherein the immunogen is an inactivated Helicobacter pylori extract; the inactivated Helicobacter pylori extract is obtained by inactivating Helicobacter pylori cells with formaldehyde and then homogenizing and crushing them under high pressure. The present invention combines the inactivated Helicobacter pylori extract with an adjuvant, which has a very strong protective effect, and its application in the development of Helicobacter pylori vaccines has a high-value application prospect.

[0022] Furthermore, the present invention provides a method for preparing an inactivated Helicobacter pylori extract in an inactivated Helicobacter pylori vaccine (i.e., a process for extracting inactivated Helicobacter pylori). In one of the more specific and preferred embodiments, the steps include: (1) Cultivation and harvesting of Helicobacter pylori

[0023] ① Resuscitation of strains: Spread the preserved strain SS1 on brain heart infusion blood agar plates under microaerobic conditions (10% CO 2 , 5%O 2 、85%N 2 ) and cultured at 37°C for 48 h.

[0024] ②Liquid culture: scrape freshly revived bacterial moss from the plate and suspend it in Hp liquid culture medium, immediately take 1 ml and inoculate it into 19 ml sterile Hp liquid culture medium, culture the bacterial liquid at 37°C, 160 rpm under microaerobic conditions for 36 hours, and collect the bacteria.

[0025] (2) Preparation of Helicobacter pylori inactivated extract

[0026] ① Inactivation of bacteria: Helicobacter pylori Hp was cultured in liquid, and after the bacteria were harvested, they were dissolved and washed 5 times with PBS, at 8000rpm, for 5min. The concentration was adjusted to 30mg / ml, and the Hp bacteria were resuspended in PBS solution with 0.4% formaldehyde, and inactivated at 25℃ for 16h. The inactivated bacteria were washed 5 times with PBS, at 8000rpm, for 5min.

[0027] ②Preparation by high-pressure homogenization: Hp inactivated bacterial solution, high-pressure homogenizer, high-pressure homogenization at 600 bar, low temperature, crushing 3 times; collecting the crushed liquid.

[0028] Furthermore, the present invention provides a new immunization route for Helicobacter pylori inactivated vaccine, which is first injected and then orally immunized. After the extract is used as an antigen and an adjuvant to prepare a vaccine and then immunized Balb / C mice, it is observed that it can induce mice to produce strong humoral immune responses and cellular immune responses.

[0029] Aluminum hydroxide adjuvant is the only adjuvant approved for human vaccines so far and is widely used. Aluminum hydroxide adjuvant induces the body to produce humoral immune protection by inducing Th2 type immune response, and can further enhance the immune response by directly or indirectly stimulating dendritic cells to activate complement and induce cytokine release. The present invention makes full use of the inactivated bacteria of Helicobacter pylori as antigens, combines with aluminum adjuvants for injection immunization, and then takes it orally, which can produce serum, gastric and intestinal antibodies, has a very strong protective effect, and is applied to the development of Helicobacter pylori vaccines with high-value application prospects.

[0030] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] The endpoints and any values ​​of the ranges disclosed in this specification are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0032] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "specific implementations", or "some specific implementations" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the embodiment of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0033] In the examples provided in this specification, if no specific techniques or conditions are specified, the techniques or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0034] Example 1

[0035] This example illustrates the method for obtaining the inactivated Helicobacter pylori vaccine of the present invention and its effect.

[0036] 1. Cultivation and harvest of Helicobacter pylori

[0037] ① Resuscitation of strains: Spread the preserved strain SS1 on brain heart infusion blood agar plates under microaerobic conditions (10% CO 2 , 5% O 2 , 85% N 2 ), 37°C, culture for 48h.

[0038] ②Liquid culture: scrape freshly revived bacterial moss from the plate and suspend it in Hp liquid culture medium, immediately take 1 ml and inoculate it into 19 ml sterile Hp liquid culture medium, culture the bacterial liquid at 37°C, 160 rpm under microaerobic conditions for 36 hours, and collect the bacteria.

[0039] 2. Preparation of Helicobacter pylori inactivated extract

[0040] ① Inactivation of bacteria: Helicobacter pylori Hp was cultured in liquid, and after the bacteria were harvested, they were dissolved and washed 5 times with PBS, at 8000rpm, for 5min. The concentration was adjusted to 30mg / ml, and the Hp bacteria were resuspended in PBS solution with 0.4% formaldehyde, and inactivated at 25℃ for 16h. The inactivated bacteria were washed 5 times with PBS, at 8000rpm, for 5min.

[0041] ②Preparation by high-pressure homogenization: Hp inactivated bacterial solution, high-pressure homogenizer, high-pressure homogenization at 600 bar, low temperature, crushing 3 times; collecting the crushed liquid.

[0042] 3. Animal experiment design

[0043] ① Preparation of candidate vaccines: Aluminum hydroxide is used as an adjuvant, mixed with inactivated Helicobacter pylori extract and injected into Hp-infected mouse model to observe the immune effect.

[0044] ②Immunization route and dose: Immunization route: Inactivated H. pylori whole bacteria plus aluminum hydroxide adjuvant was injected 1 week after immunization, and inactivated whole bacteria were orally immunized twice, with an interval of 2 weeks. Mice were killed 2 weeks after the last immunization for immunological detection.

[0045] ③Immunization steps: 8-10 week old Balb / C female mice were deprived of food and water for 6 hours before oral administration, and each mouse was gavage-fed with 0.3 ml.

[0046] The specific groups and treatment methods are shown in Table 1 below.

[0047] Table 1

[0048] 4. Pharmacology and efficacy research

[0049] ELISA was used to detect the changes in the levels of Hp-specific serum IgG, IgA and salivary sIgA in immunized mice. ELISpot was used to detect the relative differences in IFN-γ and IL-4 in the gastric mucosa of mice after vaccination. The immune challenge protection test was used to detect the protective effect after immunization.

[0050] 5. Detection method

[0051] (1) Collection of serum from mouse samples

[0052] ① Preparation of serum samples: 14 days after the last immunization, 5 mice were selected, their eyeballs were removed and blood was collected. The serum was separated and stored at -70°C for testing.

[0053] ② Preparation of gastric mucosal samples: After blood collection, mice were killed by dislocation, soaked in 75% alcohol, the abdominal cavity was opened, and the stomach was cut. The stomach was cut longitudinally from the middle along the pylorus O cardia line, and the stomach was divided into two parts. It was placed in a sterile centrifuge tube, and 0.5 ml of 20 mmol / L PBS (pH 7.4, containing protease inhibitors) was added. The mixture was shaken and mixed, and centrifuged at 4°C and 12000 r / min. The supernatant was collected and stored at -70°C for testing.

[0054] ③ Intestinal mucus sample: Collect 2 cm of the intestinal segment close to the ileocecal part, lay it flat on filter paper, cut it longitudinally, put it into a sterile tube, add 0.5 mL of 20 mmol / L PBS containing protease inhibitors, shake and mix, centrifuge at 4°C and 12000 r / min, collect the supernatant, package it, and store it at -70°C for testing.

[0055] (2) Serum specific antibody detection

[0056] ① Serum IgG antibody detection: dilute the test serum at 1:500 with antibody diluent, add to ELISA plate coated with rabbit anti-Helicobacter pylori polyclonal antibody (pAb), 100µL / well, 37℃, 60min, wash 4 times with washing solution, then add HRP-labeled goat anti-mouse IgG (1:20000 dilution, BA1050, Wuhan Boster Company), 37℃, 30min, wash 4 times with washing solution, add OPD substrate colorimetric solution, react at room temperature in the dark for 30min, terminate the reaction with 50µL stop solution, use PBS wells as blank controls, and measure the OD value of each well at 492nm.

[0057] ② Serum IgA antibody detection: dilute the test serum 1:100 with antibody diluent, add to ELISA plate coated with rabbit anti-Helicobacter pylori polyclonal antibody (pAb), 100µL / well, 37℃, 60min, wash 4 times with washing solution, add biotin-labeled goat anti-mouse IgA (1:20000 dilution, Shenzhen Jingmei Company), 100µL / well, 37℃, 30min, wash 4 times with washing solution, add HRP-labeled Avidin (1:5000, Shenzhen Jingmei Company), 100µL / well, 37℃, 30min, wash 4 times with washing solution, add OPD substrate colorimetric solution, react at room temperature in the dark for 30min, terminate the reaction with 50µL stop solution, use PBS wells as blank controls, and measure the OD value of each well at 492nm.

[0058] ③ Detection of serum IgG1 and IgG2a: dilute the test serum with antibody diluent at 1:100, add to ELISA plate coated with rabbit anti-Helicobacter pylori polyclonal antibody (pAb), 100µL / well, 37℃, 60min, wash 4 times with washing solution, add HRP-labeled goat anti-mouse IgG1 or IgG2a (1:5000 dilution, Shenzhen Jingmei Company), 100µL / well, 37℃, 60min, wash 4 times with washing solution, add OPD substrate colorimetric solution, react at room temperature in the dark for 30min, terminate the reaction with 50µL stop solution, use PBS wells as blank controls, and measure the OD value of each well at 492nm.

[0059] The specific groups and test results are shown in Table 2 below.

[0060] Table 2

[0061] Table 2 shows the serum IgG antibody levels of mice in each group. As shown in Table 2, the experimental groups 1, 2, and 3 had significant antibody production compared with the control group. This shows that the inactivated bacteria as a vaccine can cause mice to produce serum IgG, IgA, IgG1, and IgG2a antibodies.

[0062] (3) Detection of specific antibodies sIgA in gastric mucus and intestinal mucus samples

[0063] Gastric mucus samples (1:5) and intestinal mucus samples (1:5) were diluted with antibody diluent, 100 µL / well was added to the coated ELISA plate, incubated at 37°C for 60 min, washed 4 times with washing buffer, Biotin-labeled goat anti-mouse IgA (1:1000 dilution) was added, 100 µL / well was added, incubated at 37°C for 60 min, washed 4 times with washing buffer, HRP-labeled Avidin (1:5000 dilution) was added, 100 µL / well was added, incubated at 37°C for 60 min, washed 4 times with washing buffer, OPD substrate colorimetric solution was added, reacted at room temperature in the dark for 30 min, 50 µL stop solution was used to terminate the reaction, PBS wells were used as blank controls, and the OD value of each well was measured at 492 nm.

[0064] The specific groups and the test results of sIgA antibody levels (OD492) of mice in each group are shown in Table 3 below.

[0065] Table 3

[0066] Table 3 shows the specific antibody sIgA levels in the gastric mucus and intestinal mucus samples of each group of mice. As shown in Table 3, there are obvious antibodies in experimental groups 1, 2, and 3, while there is no significant difference in the control group. This shows that inactivated bacteria as a vaccine can cause mice to produce specific antibody sIgA antibodies in gastric mucus and intestinal mucus samples.

[0067] (4) Immune challenge protection test

[0068] H.pylori (SS1, Baosai Biotechnology), after subculture, the bacterial solution was adjusted to 1×10 9 cfu / mL, the mice in the control group and three test groups that had been deprived of food and water for 6 h in advance were gavaged with Φ0.9mm×L70mm flexible catheters, 0.3mL of bacterial solution per mouse, once in the morning and once in the afternoon, and again every other day, with food and water provided 2 h after the last gavage.

[0069] At the 4th week after the challenge, mice were killed by dislocation of the neck. 24 hours before killing, the mice were deprived of food and water, the stomach was removed, and the stomach was cut open along the greater curvature. The residual in the stomach was gently washed away with saline. Half of the gastric mucosal tissue was smeared with Hp culture medium, inoculated with three-line method, and cultured microaerophilically; the other half of the gastric mucosa was subjected to urease test, direct smear, Gram staining microscopy, and PCR detection. Refer to "Zhang Wandai, Xu Zhimin. Current status and consensus of Helicobacter pylori research1 World Chinese Journal of Digestion, 2000, 8 (10): 1084~1088" to judge the results of Hp infection. Positive culture or any two of the following positive results are Hp infection: Hp morphology (including histology, immunohistochemistry, smear), urease test or specific PCR. The infection rate %=number of infections in each group / number of survivors in each group, and the protection rate %=(infection rate of control group-infection rate of test group) / infection rate of control group were calculated.

[0070] The specific groups and test results are shown in Table 4 below.

[0071] Table 4 Protection rate of mice in each group

[0072] The results are shown in Table 4. Test group 3 has the highest protection rate.

[0073] (5) ELISpot detection of IFN-γ and IL-4 production levels

[0074] ① Preparation of spleen lymphocytes from immunized mice: After removing the eyeballs of mice and taking blood, the mice were killed by dislocating the neck and soaked in 75% ethanol for 1 min. In a biosafety cabinet or clean bench, the skin on the left abdomen was cut open to remove the spleen and peel off the adhered fat tissue, and the outer edge of the spleen was cut into serrated notches. Place a 200-mesh grinding sieve on a sterile plate, add 5 mL of separation solution (restore to room temperature and shake well before use), and use a 5 mL syringe piston to grind on the 200-mesh grinding sieve (control the strength, the grinding strength should be light, keep the sieve suspended on the bottom of the dish to grind, and avoid grinding directly on the bottom of the dish to cause a large number of cell death). After grinding is complete, rinse the sieve with grinding solution and collect the cell grinding solution. Immediately transfer the separation solution with suspended lymphocytes to a 15 mL centrifuge tube, and carefully and slowly add 1 mL of RPMI 1640 culture medium along the tube wall to the surface of the separation solution to keep the interface between the two liquid surfaces clear. Centrifuge at room temperature and 2050 rpm with a horizontal rotor for 30 min. After centrifugation, the cells in the centrifuge tube are divided into four layers from top to bottom. The first layer is the RPMI1640 culture medium layer; the second layer is the ring-shaped milky white lymphocyte layer; the third layer is the separation liquid layer; the fourth layer is the red blood cells and cell debris. Carefully pipette the second layer of lymphocytes into another 15 mL centrifuge tube containing 10 mL of sterile saline, invert and wash, centrifuge at room temperature, 1150 rpm, for 10 min. Discard the supernatant, resuspend the cells in the culture medium, count them, and place the lymphocytes in a 37°C CO 2 Keep in the incubator for later use (pay strict attention to sterile operation).

[0075] ② Activation of pre-coated plates: Add 200 μL / well of serum-free culture medium, let it stand at room temperature for 10 minutes and then remove it.

[0076] ③ Add stimulants: Add 10 μg of bacterial lysis solution to each culture well of each group, and add the adjusted cell suspension to each experimental well. The cell concentration is 2.5×10 5 After all samples and stimuli have been added, cover the plate. Place in a 37°C, 5% CO 2 Incubate the cells in an incubator for 16-24 hours.

[0077] For specific groups and test results, see Figure 1 and Figure 2 .

[0078] Figure 1 and Figure 2 The expression levels of IL-4 and IFN-γ in T lymphocytes of mice in each group after antigen stimulation are shown. Figure 1 and Figure 2 The results show that there are significant differences in test groups 1, 2, and 3. This shows that the immune effect of the injection followed by oral administration is significantly better than that of oral administration alone.

[0079] Th2 cells are effector cells that mediate humoral immune responses. IL-4 is a cytokine produced by Th2 cells. The level of IL-4 can reflect the level of humoral immune responses to a certain extent. The IL-4 detection results in this experiment showed that after specific antigen stimulation, Th2-mediated humoral immune responses can be effectively induced in mice.

[0080] Cell-mediated immunity also plays a role in the protective immune mechanism of H. pylori, and lymphocyte proliferation reaction is a comprehensive indicator for measuring the function of cellular immune response, which can reflect the body's specific cellular immune function to a certain extent. The results of this experiment show that mouse splenic lymphocytes can cause specific lymphocyte proliferation after being stimulated by specific antigens.

[0081] Th1 cells are effector cells that mediate cellular immune responses, and IFN-γ is a cytokine produced by Th1 cells. The level of IFN-γ can reflect the level of cellular immune responses to a certain extent. The IFN-γ detection results in this experiment showed that after stimulation with Helicobacter pylori whole bacterial lysate, Th1-mediated cellular immune responses can be effectively induced in mice, thus confirming that the vaccine can be effectively expressed in mice and has strong cellular immune activity.

[0082] In addition, the challenge experiment of the present invention also found that after the whole bacterial lysate plus aluminum adjuvant was injected into mice as a vaccine, it could produce a strong protective effect on mice and had high safety. At the same time, it provided a new immunization route, which was first injected and then immunized orally, and the immunization effect was better than that of a single oral administration. Compared with simple injection, the oral method is much more convenient, the popularization and vaccination speed is faster, and people's compliance is higher.

[0083] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. An inactivated Helicobacter pylori vaccine, characterized in that: The invention comprises an immunogen and an immune adjuvant. The immunogen is an inactivated extract of Helicobacter pylori. The inactivated extract of Helicobacter pylori is obtained by inactivating Helicobacter pylori cells with formaldehyde and then homogenizing and crushing them under high pressure.

2. The inactivated Helicobacter pylori vaccine according to claim 1, characterized in that: The cells were inactivated using a PBS solution containing 0.4±0.1% formaldehyde under the following conditions: 25±5℃, 16±4h.

3. The inactivated Helicobacter pylori vaccine according to claim 1 or 2, characterized in that: Before and after inactivation, Helicobacter pylori was washed with PBS solution for 5±2 times respectively; the conditions for each washing included: 8000±1000 rpm, 5±1min.

4. The inactivated Helicobacter pylori vaccine according to any one of claims 1 to 3, characterized in that The condition of high pressure homogenization is 600±100bar.

5. The inactivated Helicobacter pylori vaccine according to any one of claims 1 to 4, characterized in that: The immune adjuvant is aluminum hydroxide adjuvant.

6. The inactivated Helicobacter pylori vaccine according to any one of claims 1 to 6, characterized in that: Its dosage form is injection or oral preparation.

7. Use of the inactivated Helicobacter pylori vaccine according to any one of claims 1 to 6 in the manufacture of a medicament for creating an immune response in a subject, characterized in that: The dosage form of the drug is injection or oral preparation.

8. A pharmaceutical composition for creating an immune response in a subject, characterized in that Including the injection of the inactivated vaccine according to claim 6; also including the oral preparation of the inactivated vaccine according to claim 6.

9. A method for preventing Helicobacter pylori infection, characterized in that: The method comprises the following steps: immunizing with the inactivated Helicobacter pylori vaccine according to any one of claims 1 to 6 or the pharmaceutical composition for creating an immune response in a subject according to claim 8.

10. The method for preventing Helicobacter pylori infection according to claim 9, characterized in that: The immunization includes one injection immunization and two oral immunizations in sequence; the interval between the injection immunization and the first oral immunization is 1 week, and the interval between the two oral immunizations is 2 weeks.